Wall Street brokerages forecast that Omeros Co. (NASDAQ:OMER) will report sales of $3.07 million for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Omeros’ earnings. The lowest sales estimate is $2.63 million and the highest is $3.50 million. Omeros reported sales of $21.66 million during the same quarter last year, which indicates a negative year over year growth rate of 85.8%. The business is scheduled to report its next earnings report on Thursday, November 8th.

On average, analysts expect that Omeros will report full year sales of $14.83 million for the current year, with estimates ranging from $9.32 million to $20.33 million. For the next year, analysts forecast that the company will report sales of $97.98 million, with estimates ranging from $25.26 million to $170.70 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that follow Omeros.

Omeros (NASDAQ:OMER) last issued its quarterly earnings results on Thursday, August 9th. The biopharmaceutical company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.04). The business had revenue of $1.70 million for the quarter, compared to analysts’ expectations of $1.84 million. During the same quarter in the previous year, the business posted ($0.33) EPS. The company’s quarterly revenue was down 90.1% compared to the same quarter last year.

A number of equities research analysts recently weighed in on OMER shares. Zacks Investment Research upgraded Omeros from a “hold” rating to a “buy” rating and set a $25.00 price objective on the stock in a research report on Saturday, July 28th. HC Wainwright set a $34.00 target price on Omeros and gave the stock a “buy” rating in a report on Tuesday, July 24th. Maxim Group boosted their price objective on Omeros from $25.00 to $32.00 and gave the company a “buy” rating in a research note on Friday, August 10th. Seaport Global Securities started coverage on Omeros in a research note on Thursday, July 12th. They issued a “buy” rating and a $30.00 price objective on the stock. Finally, ValuEngine raised Omeros from a “hold” rating to a “buy” rating in a research note on Friday, July 6th. One analyst has rated the stock with a sell rating, six have issued a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $27.56.

In other Omeros news, VP Marcia S. Kelbon sold 40,723 shares of the business’s stock in a transaction that occurred on Friday, July 27th. The shares were sold at an average price of $21.56, for a total transaction of $877,987.88. Following the completion of the transaction, the vice president now owns 219,645 shares in the company, valued at approximately $4,735,546.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Marcia S. Kelbon sold 7,529 shares of the business’s stock in a transaction that occurred on Friday, August 31st. The stock was sold at an average price of $25.75, for a total transaction of $193,871.75. Following the transaction, the vice president now owns 227,645 shares of the company’s stock, valued at approximately $5,861,858.75. The disclosure for this sale can be found here. Insiders own 12.10% of the company’s stock.

Several large investors have recently modified their holdings of OMER. BlueMountain Capital Management LLC purchased a new stake in shares of Omeros during the 2nd quarter worth approximately $118,000. Quad Cities Investment Group LLC purchased a new stake in Omeros in the 2nd quarter valued at $161,000. Belpointe Asset Management LLC purchased a new stake in Omeros in the 2nd quarter valued at $204,000. Cypress Capital Group raised its position in Omeros by 120.0% in the 1st quarter. Cypress Capital Group now owns 22,000 shares of the biopharmaceutical company’s stock valued at $246,000 after purchasing an additional 12,000 shares during the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new stake in Omeros in the 2nd quarter valued at $274,000. Institutional investors and hedge funds own 48.11% of the company’s stock.

NASDAQ:OMER traded up $0.49 during mid-day trading on Wednesday, hitting $13.99. The company had a trading volume of 607,922 shares, compared to its average volume of 1,037,468. Omeros has a fifty-two week low of $8.36 and a fifty-two week high of $27.00. The company has a current ratio of 3.95, a quick ratio of 3.94 and a debt-to-equity ratio of -2.31. The firm has a market capitalization of $1.19 billion, a price-to-earnings ratio of -17.71 and a beta of 3.49.

Omeros Company Profile

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

See Also: What are trading strategies for the 52-week high/low?

Get a free copy of the Zacks research report on Omeros (OMER)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.